Cargando…
P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429641/ http://dx.doi.org/10.1097/01.HS9.0000847968.95263.25 |
| _version_ | 1784779519020761088 |
|---|---|
| author | Leabman, M. K. Hernandez, G. Ng, C. M. Tang, J. Pandya, D. Hart, K. C. Li, K. Hinton, P. R. So, J. Qazi, I. Cheah, C. Y. Kim, W. S. Budde, E. Gopal, A. K. Manley, T. Takimoto, C. H. Sinclair, A. M. Carroll, S. F. Keyt, B. A. Kotturi, M. F. |
| author_facet | Leabman, M. K. Hernandez, G. Ng, C. M. Tang, J. Pandya, D. Hart, K. C. Li, K. Hinton, P. R. So, J. Qazi, I. Cheah, C. Y. Kim, W. S. Budde, E. Gopal, A. K. Manley, T. Takimoto, C. H. Sinclair, A. M. Carroll, S. F. Keyt, B. A. Kotturi, M. F. |
| author_sort | Leabman, M. K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429641 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94296412022-08-31 P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA Leabman, M. K. Hernandez, G. Ng, C. M. Tang, J. Pandya, D. Hart, K. C. Li, K. Hinton, P. R. So, J. Qazi, I. Cheah, C. Y. Kim, W. S. Budde, E. Gopal, A. K. Manley, T. Takimoto, C. H. Sinclair, A. M. Carroll, S. F. Keyt, B. A. Kotturi, M. F. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429641/ http://dx.doi.org/10.1097/01.HS9.0000847968.95263.25 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Leabman, M. K. Hernandez, G. Ng, C. M. Tang, J. Pandya, D. Hart, K. C. Li, K. Hinton, P. R. So, J. Qazi, I. Cheah, C. Y. Kim, W. S. Budde, E. Gopal, A. K. Manley, T. Takimoto, C. H. Sinclair, A. M. Carroll, S. F. Keyt, B. A. Kotturi, M. F. P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_full | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_fullStr | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_full_unstemmed | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_short | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_sort | p1276: dose response profile of igm-2323, a cd20xcd3 igm bispecific t cell engager, in translational models supports phase 2 dose selection in non-hodgkin’s lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429641/ http://dx.doi.org/10.1097/01.HS9.0000847968.95263.25 |
| work_keys_str_mv | AT leabmanmk p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT hernandezg p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT ngcm p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT tangj p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT pandyad p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT hartkc p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT lik p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT hintonpr p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT soj p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT qazii p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT cheahcy p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT kimws p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT buddee p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT gopalak p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT manleyt p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT takimotoch p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT sinclairam p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT carrollsf p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT keytba p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT kotturimf p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma |